Patents by Inventor Steven GOURLAY

Steven GOURLAY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for Treating Immune Thrombocytopenia by Administering (R)-2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy- Phenyl) Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4-Methyl-4-[4-(Oxetan-3-YL)Piperazin-1-YL]Pent-2-Enenitrile
    Publication number: 20230124267
    Abstract: Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed.
    Type: Application
    Filed: September 16, 2022
    Publication date: April 20, 2023
    Applicant: Principia Biopharma Inc.
    Inventors: Steven Gourlay, Ann Neale, Philip Nunn, Claire Langrish, Olga Bandman, Dolca Thomas
  • Salts and Solid Form of a BTK Inhibitor
    Publication number: 20220370459
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 24, 2022
    Publication date: November 24, 2022
    Applicant: Principia Biopharma, Inc.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • Salts and solid form of a BTK inhibitor
    Patent number: 11369613
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: June 28, 2022
    Assignee: Principia Biopharma Inc.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • METHODS FOR TREATING IMMUNE THROMBOCYTOPENIA BY ADMINISTERING (R)-2-[3-[4-AMINO-3-(2-FLUORO-4-PHENOXY-PHENYL)PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]PIPERIDINE-1-CARBONYL]-4-METHYL-4-[4-(OXETAN-3-YL)PIPERAZIN-1-YL]PENT-2-ENENITRILE
    Publication number: 20210106584
    Abstract: Methods for treating immune thrombocytopenia comprising administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts thereof are also disclosed.
    Type: Application
    Filed: October 13, 2020
    Publication date: April 15, 2021
    Inventors: Steven GOURLAY, Ann NEALE, Philip NUNN, Claire LANGRISH, Olga BANDMAN, Dolca THOMAS
  • Treatment of pemphigus
    Patent number: 10946008
    Abstract: The present disclosure provides methods of treating with a BTK inhibitor a blistering disease, in particular pemphigus vulgaris or pemphigus folliaceous in a mammal, use of a BTK inhibitor as a replacement therapy for corticosteroid therapy for diseases treatable with a corticosteroid, such as autoimmune or inflammatory disease and in particular where corticosteroids are used as first or second line therapy, and pharmaceutical formulations comprising the same.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: March 16, 2021
    Assignee: Principia Biopharma Inc.
    Inventor: Steven Gourlay
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20210015821
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 5, 2020
    Publication date: January 21, 2021
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza MASJEDIZADEH, Steven Gourlay
  • Salts and solid form of a BTK inhibitor
    Patent number: 10828307
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: November 10, 2020
    Assignee: Principia Biopharma Inc.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • TREATMENT OF PEMPHIGUS
    Publication number: 20200101059
    Abstract: The present disclosure provides provides methods of treating with a BTK inhibitor a blistering disease, in particular pemphigus vulgaris or pemphigus folliaceous in a mammal, use of a BTK inhibitor as a replacement therapy for corticosteroid therapy for diseases treatable with a corticosteroid, such as autoimmune or inflammatory disease and in particular where corticosteroids are used as first or second line therapy, and pharmaceutical formulations comprising the same.
    Type: Application
    Filed: October 4, 2019
    Publication date: April 2, 2020
    Applicant: Principia Biopharma Inc.
    Inventor: Steven GOURLAY
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20200038405
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 8, 2019
    Publication date: February 6, 2020
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza MASJEDIZADEH, Steven GOURLAY
  • Treatment of pemphigus
    Patent number: 10485797
    Abstract: The present disclosure provides methods of treating with a BTK inhibitor a blistering disease, in particular pemphigus vulgaris or pemphigus folliaceous in a mammal, use of a BTK inhibitor as a replacement therapy for corticosteroid therapy for diseases treatable with a corticosteroid, such as autoimmune or inflammatory disease and in particular where corticosteroids are used as first or second line therapy, and pharmaceutical formulations comprising the same.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: November 26, 2019
    Assignee: PRINCIPIA BIOPHARMA INC.
    Inventor: Steven Gourlay
  • Salts and solid form of a BTK inhibitor
    Patent number: 10456403
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: October 29, 2019
    Assignee: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20190076435
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]pyiperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 29, 2018
    Publication date: March 14, 2019
    Applicant: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza MASJEDIZADEH, Steven GOURLAY
  • Salts and solid form of a BTK inhibitor
    Patent number: 10092569
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 9, 2018
    Assignee: PRINCIPIA BIOPHARMA INC.
    Inventors: Mohammad Reza Masjedizadeh, Steven Gourlay
  • TREATMENT OF PEMPHIGUS
    Publication number: 20180050027
    Abstract: The present disclosure provides methods of treating with a BTK inhibitor a blistering disease, in particular pemphigus vulgaris or pemphigus folliaceous in a mammal, use of a BTK inhibitor as a replacement therapy for corticosteroid therapy for diseases treatable with a corticosteroid, such as autoimmune or inflammatory disease and in particular where corticosteroids are used as first or second line therapy, and pharmaceutical formulations comprising the same.
    Type: Application
    Filed: December 18, 2015
    Publication date: February 22, 2018
    Inventor: Steven GOURLAY
  • SALTS AND SOLID FORM OF A BTK INHIBITOR
    Publication number: 20170065591
    Abstract: Disclosed herein are processes for preparing 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile free base (compound (I)), salts of compound (I) and solid state form of said salts. Also disclosed herein are pharmaceutical compositions comprising such salts and solid state form thereof and methods of treating cancer, autoimmune, and inflammatory diseases using compound (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 20, 2015
    Publication date: March 9, 2017
    Inventors: Mohammad Reza MASJEDIZADEH, Steven GOURLAY